Takeda Pharma - TAK Net earnings per share (EPS TTM)

Financial pressure from debt and patents impacts expenses, which is why the trailing twelve-month net income per share from GURU.Markets is used for analysis, where 0.06 shows the current value of the metric. Takeda Pharmaceutical (TAK) bases its business efficiency on robotic production, while the stability of this veteran Japanese behemoth is ensured by a strong workforce and a focus on R&D.
Analytical breakdowns for Takeda Pharmaceutical

The TTM EPS metric aggregates net income over the last four quarters, allocating it per share to eliminate distortions from issuance. For Takeda Pharmaceutical (TAK), a leader in rare disease therapy, the company's trailing 12-month earnings per share reflect the efficiency of innovation capitalization, helping investors determine whether the current stock value is justified or indicates a risk of overpayment.